Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
LONDON, April 11, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and...
-
- Study in the treatment of Dravet syndrome – a rare and severe form of epilepsy in children with no FDA-approved treatments - - Primary endpoint achieved with high statistical significance...
-
-Three Phase 3 Epidiolex clinical trials fully recruited above target sample size – on track for initial data in March 2016- -Conference Call Today at 8:00 a.m. EST, 1:00 p.m. GMT- LONDON, Feb. ...
-
LONDON, Feb. 04, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and...
-
LONDON, Feb. 02, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing...
-
LONDON, Dec. 24, 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and...
-
- Three Phase 3 Epidiolex Clinical Trials Fully Recruited Above Target Sample Size – on Track for Initial Data in Q1 2016 - - Significant Clinical Activity in Multiple Cannabinoid Pipeline...
-
As previously announced, seven posters relating to the physician sponsored Expanded Access Program for Epidiolex have been presented at the American Epilepsy Society Annual Meeting across Sunday,...
-
LONDON, Nov. 30, 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing...
-
LONDON, Nov. 25, 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing...